BACKGROUND: Obesity induces significant changes in lipid mediators, however, the extent to which these changes persist after weight loss has not been investigated. SUBJECTS/METHODS: We fed C57BL6 mice a high-fat diet to generate obesity and then switched the diet to a lower-fat diet to induce weight loss. We performed a comprehensive metabolic profiling of lipid mediators including oxylipins, endocannabinoids, sphingosines and ceramides in key metabolic tissues (including adipose, liver, muscle and hypothalamus) and plasma. RESULTS: We found that changes induced by obesity were largely reversible in most metabolic tissues but the adipose tissue retained a persistent obese metabolic signature. Prostaglandin signaling was perturbed in the obese state and lasting increases in PGD 2 , and downstream metabolites 15-deoxy PGJ 2 and delta-12-PGJ 2 were observed after weight loss. Furthermore expression of the enzyme responsible for PGD 2 synthesis (hematopoietic prostaglandin D synthase, HPGDS) was increased in obese adipose tissues and remained high after weight loss. We found that inhibition of HPGDS over the course of 5 days resulted in decreased food intake in mice. Increased HPGDS expression was also observed in human adipose tissues obtained from obese compared with lean individuals. We then measured circulating levels of PGD 2 in obese patients before and after weight loss and found that while elevated relative to lean subjects, levels of this metabolite did not decrease after significant weight loss. CONCLUSIONS: These results suggest that lasting changes in lipid mediators induced by obesity, still present after weight loss, may play a role in the biological drive to regain weight.
INTRODUCTION
In America, an estimated 45 million people attempt to lose weight each year 1 and although many achieve short-term success, sustained maintenance of reduced body weight is rarely achieved. [2] [3] [4] [5] [6] [7] [8] [9] A successful weight loss program incorporating diet and lifestyle changes may lead to 10% reduction in body weight, 10 but remarkably 75-95% of people regain this weight. 2, 9, [11] [12] [13] [14] The driving forces behind weight regain include both biological and psychological factors. 4, 15, 16 Weight loss is associated with compensatory decreases in energy expenditure, which oppose the maintenance of the lower weight and promote weight regain. [17] [18] [19] [20] [21] Furthermore, changes in circulating levels of peripheral modulators important in appetite regulation, such as leptin, peptide PYY, cholecystokinin, insulin, ghrelin and gastric inhibitory polypeptide, as well as hunger, remain significantly different from baseline one year after weight loss and play an important role in weight regain. 22 Obesity induces significant changes in the metabolome; [23] [24] [25] [26] [27] however, the extent to which these changes persist after weight loss has not been investigated. We fed C57BL6 mice a high-fat diet (60% calories from fat, HFD) to generate obesity and then switched the diet to a lower-fat diet (10% calories from fat, LFD) to induce weight loss as previously described. 28 In this study, we have used targeted metabolomics to study changes in lipid mediators in insulin target tissues (liver, adipose, muscle, hypothalamus) and plasma in obesity and after weight loss in mice. We performed comprehensive metabolic profiling of lipid mediators (including oxylipins, endocannabinoids, sphingosines and ceramides) that have been implicated in obesity-associated co-morbidities such as insulin resistance, diabetes and cardiovascular disease. 26, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Oxylipins (eicosanoids, docosanoids and octadecanoids) are potent bioactive metabolites that are involved in inflammatory signaling and play important roles in obesity-induced inflammation and insulin resistance. 26, 34, 35, [39] [40] [41] 43 Oxylipins are derived from the oxygenation of polyunsaturated fatty acids (PUFAs) by three families of enzymes; cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome p450 (CYP). 43 The 12-LOX-derived oxylipins are induced in the obese state and studies have shown these oxylipins play an important role in mediating inflammation and result in adipocyte dysfunction. 44 The endocannabinoid system plays an important role in energy storage, nutrient transport and insulin sensitivity. 29 In the CNS endocannabinoids stimulate food intake through their interactions with the leptin-regulated neurocircuitary and can work as neuromodulators to directly regulate and release classical neurotransmitters. 45, 46 Endocannabinoids act on peripheral tissues including adipose, liver and muscle and overactive endocannabinoid tone is associated with obesity. 29, 30, [36] [37] [38] Ceramides are bioactive sphingolipids that accumulate in obesity resulting in the development of insulin resistance. [31] [32] [33] 42, 47 Ceramides are synthesized by a family of six ceramide synthases (CerS) in mammals, which produce ceramides with different Nlinked acyl chains of various lengths. Inhibition of ceramide synthesis has been shown to improve systemic metabolism and obesity-induced insulin resistance. 33, 42 While many studies have identified changes in lipid mediators in obesity, the extent to which weight loss reverses these obesityinduced changes has not yet been studied. The mechanisms driving weight rebound are complex and largely unknown; therefore, understanding the barriers to maintaining weight loss is crucial for the prevention of relapse to obesity. We hypothesized that some metabolites that are induced or repressed in the obese state remain so even after weight loss and these 'persistent' metabolites may play a role in driving weight regain. Metabolites that are induced by obesity and not changed upon weight loss may represent therapeutic targets for the maintenance of weight loss.
MATERIALS AND METHODS

In vivo mouse studies
All experiments were approved by and conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego. Male C57BL6 mice were fed normal chow until 12 weeks of age and then randomly divided into three groups termed LFD (low-fat diet, 10% fat; D12450B, Research Diets), HFD (high-fat diet, 60% fat; D12492, Research Diets) and SWD (switch diet from HFD to LFD). The LFD and HFD groups were fed ad libitum for 18 weeks. The SWD group were fed HFD for 9 weeks and then switched to LFD for a further 9 weeks after which their body weights had returned to a similar mass as the LF group (n = 8 per group). Group sizes were selected based on previous similar studies. 28 All groups were sacrificed at 30 weeks of age and the tissues (hypothalamus, liver and epididymal adipose tissue) dissected and frozen immediately in liquid nitrogen. Glucose tolerance tests (GTTs) were performed at 3 and 8 weeks after the diet switch as previously described. 48 Briefly, mice were fasted for 6 h and then injected with glucose (ip, 1 g kg − 1 dose) and blood samples drawn at 10, 30, 60 and 90 min to monitor glucose excursion over time. A selective inhibitor of hematopoietic prostaglandin D synthase (HQL-79, 30 mg kg − 1 (Cayman Chemical, Ann Arbor, MI, USA) or vehicle control (saline) was administered by oral gavage for five consecutive days to C57BL6 mice fed HFD 8 weeks, from 12 weeks of age. Body weight and food intake were measured daily at 1000 hours prior to gavage and at the end of the study mice were killed and plasma and adipose tissue collected, n = 12 mice per group.
Sample extraction
Oxylipins, endocannabinoids and ceramides were isolated using a 96-well Ostro Pass Through Sample Preparation Plate (Waters Corp, Milford, MA, USA) n = 6 samples per tissue/per group. For plasma, 50 μl of sample was added to the plate wells and spiked with a 5 μl anti-oxidant solution (0.2 mg ml − 1 solution BHT/EDTA in 1:1 methanolwater) and 10 μl 1000 nM deuterated surrogates. Next, isopropanol w/ 10 mM ammonium formate and 1% formic acid (150 μl) was added and aspirated three times to mix. Following this step, the mixture was eluted into glass inserts, dried and reconstituted in the same manner as the tissue samples (as described below). Tissue samples were pulverized (liver~20-25 mg, adipose 6-10 mg, muscle 6-10 mg hypothalamus~0.5-2.5 mg) and added to 2 ml polypropylene tubes spiked with 5 μl anti-oxidant solution (0.2 mg ml − 1 solution BHT/EDTA in 1:1 methanol:water) and 10 μl of 1000 nM deuterated surrogates in methanol. A total of 50 μl of methanol was added and the tube was placed in a Geno/Grinder 2000 (SPEX Sample Prep, Metuchen, NJ, USA) for 30 s at 1350 rpm. An additional 550 μl isopropanol w/ 10 mM ammonium formate and 1% formic acid and 100 μl water was added and the tube was placed in a Geno/Grinder for an additional 30 s before being centrifuged at 10 000 g for 5 min at room temp. Supernatants were transferred into Ostro Plate wells and eluted into glass inserts containing 10 μl 20% glycerol in methanol by applying a vacuum at 15 Hg for 10 min.
Eluents were dried by vacuum centrifugation in a Genvac EZ-2 (SP Scientific, Stone Ridge, NY, USA) for 35 min at the medium BP setting, before switching to an aqueous setting for an additional 35 min. Once dry, samples were re-constituted with the internal standard 1-cyclohexylureido, 3-dodecanoic acid (Cayman Chemical) and 1-phenylureido, 3-hexanoic acid (gift from B.D. Hammock, University of California, Davis) at 100 nM (50:50 methanol:acetonitrile), vortexed 1 min, transferred to a spin filter (0.1 μm PVDF membrane, Millipore, Billerica, MA, USA), centrifuged for 3 min at 6°C at o4500 g, before transfer to 2 ml LC-MS amber vials. Extracts were stored at − 20°C until analysis by ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The internal standards were used to quantify the recovery of surrogate standards.
Lipid mediator analysis
Analytes were separated using a Waters Acquity UPLC (Waters, Milford, MA, USA) with a solvent gradient modified from previously published protocols for oxylipins, 40 endocannabinoids 39 and ceramides. 49 Samples were held at 10°C. Separated residues were detected in independent injections by negative mode electrospray ionization for oxylipins and positive mode electrospray ionization for endocannabinoids and ceramides using multiple reaction monitoring on an API 4000 QTrap (AB Sciex, Framingham, MA, USA). Analytes were quantified using internal standard methods and 5-7point calibration curves (r 2 ⩾ 0.997). Calibrants and internal standards were either synthesized (10,11-DHN, 10,11-DHHep, 10(11)-EpHep) or purchased from Cayman Chemical, Avanti Polar Lipids Inc. (Alabaster, AL, USA) or Larodan Fine Lipids (Malmo, Sweden), unless otherwise indicated. Data were processed using AB Sciex MultiQuant version 3.0.2. Lipid mediator data from this study can be accessed from http://www.metabolomicsworkbench.org, data set refs ST000593 and ST000594.
Human samples
Plasma PGD 2 levels were determined by ELISA (Cayman Chemicals) in samples obtained from obese patients before and after bariatric surgery. Specifically, blood samples were collected at the following time-points: (1) plasma samples were obtained 3 weeks prior to surgery, after which patients committed to a two to six week, 510 to 900 kcal/day diet regimen per day diet regiment. (2) Plasma samples were collected on the day of surgery, at which time the patients had lost on average 8.7 kg due to the diet regime. (3) Plasma samples were also collected 6 and 12 months after surgery, at which time the patients had lost on average 37.3 and 46.7 kg, respectively. These human samples were obtained from a larger study (ClinicalTrials.gov NCT02322073) in agreement with the principal investigator, V. Wallenius. The Regional Ethical Review Board (Gothenburg, Sweden), approved all study procedures (Dnr 682-14) and all patients were enrolled in accordance with the Helsinki Declaration. Written informed consent was obtained from all participants included in this study.
Adipocyte and stromal vascular cell isolation from adipose tissue
Adipocytes and stromal vascular cells (SVCs) were isolated as previously described. 50 Briefly, visceral adipose tissue was mechanically chopped and then digested with collagenase II for 15 min at 37°C. After passing cells through a 100-μm cell strainer and centrifugation at 1000 g for 10 min, primary adipocytes were collected from the top layer of the supernatant and the pellet containing the SVC-fraction was then incubated with red blood cell lysis buffer.
RNA isolation and q-PCR
Total RNA was isolated using TRIzol (Invitrogen Carlsbad, CA, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). For q-PCR, samples were run in a 20-μl reaction (iTaq SYBRgreen supermix; Bio-Rad, Hercules, CA, USA) using a stepOnePlus Real-Time PCR system (Applied Biosystems). Gene expression levels were calculated after normalization to the standard housekeeping gene Actb and RNA polymerase II, using the ΔΔCt method as described previously, 48 and expressed as relative mRNA levels compared with internal control. Primer sequences available upon request.
Statistics
When comparing two groups statistical analysis was performed by a oneor two-tailed Student's t-test. A two-way ANOVA with repeated measures followed by a Tukey post hoc test was used to compare multiple groups at different time points using GraphPad Prism 6, unless otherwise stated. For the lipid analysis, significance was determined by one-way ANOVA on log10-transformed data and Benjamini and Hochberg was used for false discovery rate adjustment. Significance was defined as q-value equal or o0.05. All data are expressed as mean ± s.e.m. The 'reversibility' class was defined as a significant change between the lean and obese state (qo0.05 LFD vs. HFD), which then changes back after weight loss (qo 0.05 HFD vs. SWD), while the level after weight loss is comparable with the original lean state (q40.05 SWD vs. LFD). The 'persistent' class contains metabolites that change significantly between the lean and obese state (qo 0.05 LFD vs. HFD), that do not significantly change after weight loss (q40.05 HFD vs. SWD) and the new level after weight loss is also significantly different from the original LFD level (qo 0.05 SWD vs. LFD). The third class, includes metabolites that are 'not fully reversed' after weight loss, where the metabolite is significantly changed in the obese state (LFD vs. HFD), but after weight loss, the levels are not significantly different from the HFD level (HFD vs. SWD not significant), and the new level after weight loss is not significantly different from the lean state (SWD vs. LFD not significant).
No blinding was carried out for data analysis.
RESULTS
To identify lipid mediators that are regulated by obesity or weight loss we used a model of HFD feeding to induce obesity in C57BL6 mice and then switched the diet to LFD to induce weight loss ( Figure 1a ). Mice chronically fed HFD developed obesity ( Figure 1b ) and glucose intolerance ( Figure 1c ). Switching from HFD to LFD feeding for a further 8 weeks resulted in weight loss ( Figure 1d ) and improvement in glucose tolerance (Figure 1e ) in the SWD group to a similar level as mice that were continuously fed LFD throughout the study.
Targeted lipid mediator analysis of endocannabinoids, oxylipins and ceramides in metabolic tissues (liver, adipose tissue, skeletal muscle, hypothalamus) and plasma, identified 57 metabolites that were significantly induced or repressed in the obese state compared with lean controls (Figure 2 ). Of these changes the majority were increased in the HFD-fed, obese state while only 8/57 lipids were lower in the HFD-fed mice compared with LFDfed mice (Figure 2a ). The change in expression levels of metabolites between the lean and obese state were classified as 'reversible', 'persistent' or 'not fully reversed' after weight loss. The majority of these changes (28/57 = 49%) were reversible after weight loss, while 12/57 ( = 21%) were not fully reversed and (17/57 = 30%) were persistent and did not revert back to lean state after weight loss (Figure 2b) .
The majority of changes in lipid mediators occurred in the adipose tissue (25/57 = 43%) and liver (21/57 = 36.8%), while far fewer were observed in the plasma (8/57 = 14%), muscle (2-/57 = 3.5%) and hypothalamus (1/57 = 1.8%) ( Figure 2c ). After weight loss induced by switching the diet from HFD to LFD, many of the obesity/HFD-induced changes observed in the adipose tissue were persistent and did not return to the equivalent Obesity-induced changes in lipid mediators LFD-fed levels, while no persistent changes were observed in the liver, muscle, hypothalamus or plasma. HFD feeding resulted in changes in concentration of lipids across multiple tissues (Figures 2d-f ). For example, oxylipins such as 13-HODE, 9-HOTE, 9-HEPE and 9-HODE all increased in both adipose and liver from obese, HFD-fed mice compared with lean LFD-fed mice (Figure 2d ). Endocannabinoid-like compounds 1-OG, 2-LG and LEA were all increased in HFD-fed mice compared with lean, LFD-fed mice (Figure 2e ). HFD feeding resulted in increased 1-OG in the adipose and liver; increased 2-LG in adipose and plasma; and increased LEA across adipose tissue, liver, hypothalamus and plasma compared with LFD-fed mice. HFD feeding resulted in decreased OEA in the liver but increased OEA in the plasma compared with LFD-fed mice (Figure 2e ). HFD resulted in increased C18:1 and C20 ceramide in adipose, muscle and plasma; increased C18 dihydroceramide in adipose and plasma and increased 18:1 sphingosine in adipose and liver compared with LFD-fed mice (Figure 2f ). Some of these changes were reversible upon weight loss, while some persisted at the level observed in the obese state (Figures 2d-f) .
The individual lipids that were significantly different in HFD-fed mice compared with LFD-fed mice were classified into reversible, not fully reversible and persistent classes ( Figure 3 ). The majority of changes induced by HFD feeding/obesity in the liver (Figure 3a ) plasma, muscle and hypothalamus (Figure 3b ) are reversible after weight loss. In contrast, the majority of the changes induced by HFD feeding in adipose tissue are persistent after weight loss (Figure 3c ). Of the 25 lipids that significantly change in adipose tissue after HFD feeding only 5/25 had fully reversed back to lean levels after weight loss, 3 were partially reversed while 17/25 were persistently high after weight loss. Of these persistent changes, prostaglandin signaling is perturbed with lasting increases in PGD 2 and downstream metabolites Delta-12-PGJ 2 and 15-deoxy PGJ 2 (Figures 3d and e ) in adipose tissue. Notably other cyclooxygenase-dependent metabolites including TXB 2 , 6-keto PGF1α and PGE 2 (Figure 3e ) were not induced by HFD feeding.
COX-dependent metabolites, including the prostaglandins (PGs) and thromboxanes (TXs) have broad roles in both healthy and pathological contexts. 51 COX enzymes catalyze the conversion of arachidonic acid to PGH 2 , which is converted to species including PGD 2 , PGE 2 , PGF 2α , prostacyclin (PGI 2 ) or TXA 2 by the action of specific synthases. 52 PGD 2 is further dehydrated to produce PGJ 2 , delta 12-PGJ 2 and 15-deoxy-delta 12,14-PGJ 2 . The synthesis of PGD 2 from PGH 2 can be catalyzed by two synthase enzymes termed prostaglandin D synthase (PTGDS) 53 and hematopoietic prostaglandin D synthase (HPGDS) . 54 HPGDS is widely distributed in the peripheral tissues while PTGDS is highly expressed in the central nervous system, but also expressed at lower levels in other peripheral tissues. 55 We therefore measured the expression of HPGDS and PTGDS enzymes in adipose tissue from these three diet groups. HPGDS was increased in HFD-fed mice by~10-fold compared with LFD-fed mice and the expression level remained high in the SWD group (Figure 4a) , while PTGDS was unchanged between groups (Figure 4b) . To determine the cellular source of HPGDS in adipose tissue we fractionated the adipocytes and SVCs from LFD, HFD and SWD fed mice (Figure 4c ). Levels of HPGDS were similar between adipocytes and SVCs from LFD-fed mice. However, after HFD feeding the levels of HPGDS increased significantly in both adipocytes and SVCs compared with LFDfed mice and this increase persisted in both adipocyte and SVC fractions after weight loss (Figure 4c ). In agreement with other studies, 56 we also observed persistent expression of macrophage markers after weight loss (Figures 4d and e ).
To determine whether these findings were also conserved in human subjects, we measured the levels of these enzymes in human adipose tissue biopsies taken from lean and obese patients. We previously performed microarray analysis on human adipose tissue biopsies 57 and mined this data set to determine Cycloxygenase enzymes catalyze the conversion of arachidonic acid to PGH 2 , which is converted to other species including PGD 2 , PGE 2 , PGF 2α , prostacyclin (PGI 2 ) and thromboxane (TX) A 2 by the action of specific synthases. (e) Prostaglandin levels in lean (LFD), obese (HFD-fed) and after weight loss (SWD). *Significant change between LFD and HFD, # significant change between LFD and SWD.
Obesity-induced changes in lipid mediators whether HPGDS was differentially expressed between lean and obese individuals. HPGDS levels were increased~1.95-fold compared with lean individuals (BMI 23.2 vs. 35.9) (Figure 4f ). This increase in HPGDS in adipose tissue from obese patients was also observed when we extracted the expression data from similar published studies (Figure 4g ), NCBI GEO data set GDS3679. 58 We then extracted data from studies comparing expression levels in adipose tissue before and after weight loss 59, 60 and looked at HPGDS levels to see if obesity-induced increase in HPGDS was maintained after weight loss as seen in our mouse studies. In support of the mouse data, diet-induced weight loss of up to 15% (Figure 4h ), 59 or after a very low-calorie diet for 16 weeks with average weight loss of 27.7 kg (Figure 4i) 60 did not change the expression levels of HPGDS in human adipose tissue. We also measured circulating levels of PGD 2 in obese subjects before and after gastric bypass surgery (Figures 4j and k) . Circulating levels of PGD 2 in obese patients were~2-fold higher than the clinical reference rage for normal individuals. 57,61-64 Furthermore, after substantial weight loss of~35% (average BMI reduced from 43.6 to 28.2) PGD 2 levels were unchanged one year after gastric bypass surgery.
Due to the persistent elevation of PGD 2 and HPGDS, we hypothesized that PGD 2 may play a role in food intake. Central injection of PGD 2 has previously been shown to stimulate food intake 65 but whether peripheral levels of PGD 2 could play a role in food intake is not yet known. To reduce peripheral levels of PGD 2 , we treated mice with the selective HPGDS inhibitor HQL-79. 66 Previous studies have shown that HQL-79 selectively inhibits HPGDS while not affecting PTGDS and results in lowering of PGD 2 levels. [67] [68] [69] Treatment of wild type, HFD-fed mice with HQL-79 (30 mg/kg, oral gavage) for 5 days resulted in a significant reduction in food intake (Figure 5a) , with an associated trend in reduction of body weight (P = 0.09) (Figure 5a ). Whole-adipose tissue levels of PGD 2 in whole-adipose tissue were not significantly different between the control and HQL-79 treatment groups, but the ratios between PGD 2 and other connected pathway metabolites indicate a shift toward the production of PGE 2 and PGF 2α , in addition to their metabolites, instead of PGD 2 ( Supplementary  Figure 1 ) after HQL-79 treatment.
DISCUSSION
We hypothesized that lasting changes in the metabolome after weight loss may play a role in feeding behavior and contribute to weight regain. We characterized changes in the levels of oxylipins, endocannabinoid and ceramide lipid mediators in lean, obese and weight-reduced mice. We identified lasting changes in the lipid mediators in the weight-reduced mice and identified many persistent changes specifically in adipose tissue. Of these persistent changes, prostaglandin signaling was perturbed with persistent elevation in PGD 2 and downstream metabolites 15-deoxy PGJ 2 and delta-12-PGJ 2 . In addition, levels of the enzyme responsible for PGD 2 synthesis (HPGDS) were also increased in adipose tissue in the obese state and did not decrease after weight loss in either mouse or human studies. PGD 2 plays a broad role in many biological processes including sleep, 70 analgesia 71 allergic diseases 52, 72 and food intake, where injection of PGD 2 directly into the brain increases food intake in mice. 65 Prostanoids exert a wide variety of actions in the body, which are mediated by specific receptors on plasma membranes. 73 PGD 2 acts through two receptors (DP1 and DP2 CRTH2), whereas 15-deoxy PGJ 2 can activate some peroxisome proliferator-activated receptors and inhibit proinflammatory pathways. 74 Our finding that levels of prostaglandin signaling increased in obesity are in agreement with previous published studies showing elevated PGD 2 and HPGDS in mouse adipose tissue. 75 Furthermore, transgenic overexpression of HPGDS in mice results in obesity and increased fat mass. 76 We confirm and extend these findings by showing that the obesity-induced increase in PGD 2 does not decrease after weight loss and may play a role in body weight regulation.
In human studies, prostaglandin signaling has been linked to obesity in correlation studies showing that expression of the prostaglandin synthesis enzyme PTGDS in the cerebrospinal fluid significantly correlates with levels of orexigenic neuropeptides. 77 In addition, PTGDS levels in CSF are positively correlated with visceral adipose tissue and negatively correlated with subcutaneous adipose tissue mass. 77 In our study, we have mined expression databases of human adipose tissue from lean and obese subjects and found levels of HPGDS were elevated in the obese state and did not decrease after weight loss. In addition circulating levels of PGD 2 were elevated compared with the lean reference range, and gastric bypass-induced weight loss did not decrease circulating PGD 2 levels.
The lasting changes in prostaglandin signaling in adipose tissue after weight loss suggest a possible role in weight regain. Previous studies have shown that central injection of PGD 2 stimulates food intake, 65 but whether peripheral levels of PGD 2 could play a role in food intake was not yet known. We show that inhibition of HPGDS (by oral gavage of HQL-79) results in decreased food intake and thus could be a therapeutic strategy in prevention of weight regain after weight loss. After 5 days of HQL-79 administration in HFD-fed mice the adipose tissue ratios between PGD 2 and other connected pathway metabolites indicate a shift toward PGE 2 and PGF 2α production instead of PGD 2 after HQL-79 treatment ( Supplementary Figure 1a) , however, detected levels of PGD 2 were not significantly different in whole-adipose tissue. Fractionating the adipocyte and SVCs would determine whether either cell type upregulate PGD 2 production in response to HPGDS inhibition 67 but the isolation procedure itself will likely cause alterations in metabolite levels that would no longer reflect the in vivo state 75 due to rapid degradation of PGD 2 within a few minutes. 78 Furthermore, although we give the H-PGDS inhibitor peripherally, we cannot rule out the possibility that this inhibitor may also act directly on the brain to reduce PGD 2 levels which may also play a role in the observed effects on food intake. Future studies are needed to fully understand the role of adipocyte and SVC PGD 2 levels on the regulation of food intake and energy expenditure. There are currently specific HPGDS inhibitors being developed for other indications such as asthma and chronic obstructive pulmonary disease. 79, 80 Our data strongly suggest that inhibition of HPGDS may also be beneficial to maintain weight loss and prevent weight regain.
The role of adipose tissue in the control of food intake is well established, with leptin being the most well known example, 81 but how peripheral levels of PGD 2 may affect feeding behavior is still unknown. Body weight is controlled centrally by the hypothalamus that integrates signals emanating from the periphery including gastrointestinal, hepatic and adipose tissue to control food intake and energy expenditure 82,83 PGD 2 from adipose tissue may travel via the systemic circulation, crossing the blood brain barrier and directly reach the brain. 82 However, we do not observe a significant increase in PGD 2 levels in the plasma of obese mice, which may be due to instability of this metabolite that has a halflife in the blood of o 2 mins, 78 ( Supplementary Table 1 ). Alternatively, the signal from adipose to brain may be transduced by changes in the firing rate of sensory nerve fibers. Viral tracing studies have identified afferent circuits projecting from white adipose tissue to the central nervous system, supporting the existence of a sensory pathway from white adipose tissue to the brain. 84, 85 Therefore, further investigation is needed to understand the mechanism by which adipose tissue levels of lipid mediators may regulate food intake.
Despite the persistent metabolic adaptations that act to proportionally counter efforts to reduce body weight, 17 some studies report that weight loss maintenance gets easier over time: after individuals have successfully maintained weight loss for 2-5 years the chances of longer term success greatly increases. 9 Human adipocytes turn over very slowly, and on average are only replaced every 10 years. 86, 87 Therefore, changes induced in adipocytes by obesity may be longer lasting than in cell types that are replaced more readily. In addition, the obesity-induced increase in macrophage infiltration into adipose tissue does not Obesity-induced changes in lipid mediators reverse after weight loss and these cells are still present in adipose tissue after sustained weight loss in mice. 56 Therefore, the 'metabolic memory' of adipose tissue is difficult to erase even after maintenance of weight loss. In future time course studies, it will be interesting to see if the persistent changes in the adipose metabolome will eventually reverse after a longer time frame. These studies reveal that obesity induces a lasting metabolic signature that does not resolve after weight loss. This metabolic signature resides predominantly in adipose tissue while other metabolic tissues including liver, muscle and hypothalamus return to pre-obese levels after weight loss. We show that PGD 2 signaling is implicated in food intake and that high levels of HPGDS and circulating PGD 2 are still present in human subjects despite weight loss. The metabolic characteristics of adipose tissues after weight loss could play an important role in the persistence of a biological drive to regain weight.
